Fig. 5. Effects of JNK II inhibitor and SB203580 on BMKNE-induced AGS cells. MTT–based viability assay. C-jun NH2-terminal kinase (JNK) II inhibitor (A) or SB203580 (a p38 MAPK inhibitor) (B) was administered to the AGS cells pretreated with BMKNE. The figures show means ± SEMs. * P < 0.05, † P < 0.01.